ValiRx signs deal to evaluate StingRay Bio drug candidates
10th Nov 2023 11:49
(Alliance News) - ValiRx PLC on Friday said it has signed a deal with StingRay Bio Ltd to investigate a series of drug candidates. Read More
(Alliance News) - ValiRx PLC on Friday said it has signed a deal with StingRay Bio Ltd to investigate a series of drug candidates. Read More
(Alliance News) - ValiRx PLC on Friday said it had no unpublished information that was sensitive to its share price, as it rose significantly. Read More
(Alliance News) - ValiRx PLC on Thursday reported an increased half-year loss amid higher costs, as it continued to focus on building its science-focused portfolio. Read More
(Alliance News) - ValiRx PLC on Monday said its wholly-owned subsidiary, Inaphaea BioLabs Ltd, has entered into a collaborative services agreement with Agility Life Sciences Ltd. Read More
ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphea BioLabs Ltd will partner with an unnamed UK-based biotechnology company on a phenotypic assay to investigate anti-cancer properties using patient-derived cells from Inaphea's biobank. Adds Inaphea has started internal studies on ValiRx assets s VAL301 and Cytolytix CLX001. "This defined work programme involves a multi-stage project and is expected to complete at the end of September 2023," ValiRx says. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Wednesday and not separately reported by Alliance News: Read More
ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphaea Biolabs Ltd enters agreement with OncoBone Ltd. Says OncoBone clients will be able to access Inaphaea services. Notes Inaphaea is now confirmed as a cell-based assay supplier to OncoBone. Adds Inaphaea's services are now listed on scientist.com, a database website used by biotechnology and pharmaceutical companies. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - ValiRx PLC shares fell on Friday, after it ended its evaluation agreement with Hokkaido University to research a potential drug. Read More
(Alliance News) - Stock prices in London opened higher on Friday, taking their cue from Asian and US equities, while investors weighed recent interest rate decisions. Read More
(Alliance News) - ValiRx PLC on Wednesday said it acquired the scientific assets of Imagen Therapeutics Ltd from its appointed liquidators for GBP170,000. Read More
(Alliance News) - ValiRx PLC on Wednesday said it has expanded a pre-existing agreement with the University of Barcelona to test additional molecules as possible drugs for cancer. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
ValiRx PLC - Hatfield Heath, England-based life sciences company focused on early-stage cancer therapeutics and women's health - Raises GBP1 million from placing of 9.1 million shares at 11 pence each. Also will raise up to GBP500,000 more from a broker offer to retail investors at the same price. Turner Pope Investments Ltd will run the broker offer. Every four shares in the placing and retail offer come with a warrant to buy another new share at 14p over the next three years. Calls February 2 general meeting to approve the fund raise. Currently has a GBP10.1 million market capitalisation. Read More
(Alliance News) - ValiRx PLC on Tuesday saw shares drop, after extending its evaluation agreement with Hokkaido University to conduct further experimental testing. Read More